China Medical System Honored with 2025 Listed Company “Shareholder Return Crystal Ball Award” and “ESG Crystal Ball Award” by Weekly on Stocks

The list of winners for the 2025 Crystal Ball Awards for Listed Companies organized by Weekly on Stocks was recently unveiled. China Medical System Holdings Limited (the “Group” or “CMS”) has been honored with two prestigious awards — the 2025 “Shareholder Return Crystal Ball Award“ and the “ESG Crystal Ball Award“ for Listed Companies — in recognition of its outstanding capital market performance and leading ESG practices. Launched in 2007 by Weekly on Stocks, the “Crystal Ball Awards” have become one of the three most influential annual award programs in China’s capital market, renowned for its professionalism, authority, and impartiality. The awards enjoy broad recognition among regulators, listed companies, and institutional investors. CMS has entered a new stage as “an innovation-driven, multinational pharmaceutical company with a fully integrated R&D, manufacturing, and commercialization value chain“. Currently, the Group’s innovation pipeline has expanded to approximately 40 products, among which 5 innovative drugs have been approved for marketing, and another 5 products are under review for marketing […]

China Medical System: Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”), for which the Group holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights, has obtained the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 29 September 2025. The NMPA has agreed to conduct the clinical trial of MG-K10 for the treatment of Chronic Obstructive Pulmonary Disease (COPD).   About MG-K10 MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, for the treatment of type 2 inflammatory diseases. Currently marketed anti-IL-4Rα drugs require biweekly dosing, while MG-K10 has a longer half-life, enabling a four-week dosing frequency. It is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be […]

China Medical System: Approval of Phase III Drug Clinical Trials for Additional Chronic Spontaneous Urticaria Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Group on 22 April 2025 for details) together with its subsidiaries holding the co-development rights (except for atopic dermatitis (AD)) and the exclusive commercialization rights of Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”) received the drug clinical trial approval notice issued by National Medical Products Administration (“NMPA”) on 28 September 2025. The NMPA has agreed to conduct a Phase III clinical trial of MG-K10 for chronic spontaneous urticaria (CSU).   About MG-K10 MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, for the treatment of type 2 inflammatory […]

15 Years of Dedication, Pioneering the Future with Innovation丨China Medical System’s 15th Anniversary of Listing on the Hong Kong Stock Exchange

CMS Honored with Dual Accolades: “Industry-Leading Pharmaceutical Enterprise” and “Best Listed Company”

Recently, China Medical System Holdings Limited (“CMS” or the “Group”) achieved two major honors in the fields of pharmaceutical innovation and the capital market. On September 24, at the 2025 China Healthcare Decision-Makers Conference (2025 CHDC) and the Celebration of Decade-long Achievements in China’s Innovative Drugs in Beijing, CMS was listed in the “Industry-Leading Pharmaceutical Enterprises,” recognized for its differentiated innovative pipelines, outstanding commercialization capabilities, and forward-looking presence in emerging overseas markets. On September 26, at the 2025 Global Commercial Newspaper Economic Forum and the “Golden Kunpeng” China Financial Value Ranking Event held in Hong Kong, CMS was awarded the “Best Listed Company” prize for its proactive transformation breakthroughs, outstanding capital market performance, and excellence in ESG practices. The “Industry-Leading Pharmaceutical Enterprise” selection is based on full-industry-chain data from PharmCube, assessing companies across multiple dimensions including overall pipeline competitiveness, the clinical and commercial value of core products, and international expansion. It identifies benchmark enterprises that drive innovation as […]

IND Approval for Self-developed Product: CMS’s Innovative Drug GnRH Receptor Antagonist CMS-D002 is Approved for Uterine Fibroids Indication

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that innovative drug CMS-D002 Capsules (“CMS-D002”) self-developed by the Group, has been officially approved by National Medical Products Administration (“NMPA”) of drug clinical trial on 25 September 2025. The approval was obtained on 26 September 2025. NMPA has agreed to conduct a clinical trial evaluating the safety and efficacy of CMS-D002 in the treatment of uterine fibroids.   About Product CMS-D002 CMS-D002 is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. GnRH is a decapeptide hormone synthesized by neuroendocrine cells in the hypothalamus and is an important factor in regulating the release of reproductive system hormones. CMS-D002 competitively binds to GnRH receptors on the pituitary gland with endogenous GnRH, blocking the hypothalamic-pituitary-gonadal axis at the central nervous system level, reducing the release of endogenous Follicle-stimulating hormone (FSH) and Luteinizing hormone(LH), thereby inhibiting the secretion of downstream estrogen, progesterone and testosterone, and alleviating the progression […]

China Medical System: Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

The phase 3 clinical trial of ruxolitinib cream in patients with mild to moderate AD in China met its primary endpoint,at Week 8, 63.0% of patients achieved IGA 0/1, with ≥2-grades of reduction from baseline (vs 9.2% placebo, P<0.001); for the key secondary endpoint, while 78.0% of patients achieved EASI 75 response (vs 15.4% placebo, P<0.001). Overall, the ruxolitinib cream was safe and well-tolerated.   Ruxolitinib cream(a selective JAK1/JAK2 inhibitor) is the first topical JAK inhibitor approved for use by the S. FDA[1].   The Group isactively moving forward the Product’s NDA for the AD indication in China.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Company on 22 April 2025 for details) together with its subsidiaries, […]

China Medical System Signed Collaboration Agreements for Class 1 Innovative Biologics Vecantoxatug Injection (Passive Immunization Against Tetanus) and Silevimig Injection (Passive Immunization Against Rabies)

Vecantoxatug is a passive immunization agent with an excellent safety profile, which delivers superior protection compared with HTIG, providing rapid and durable immune defense for patients Silevimig is the world’s first recombinant, fully human bispecific antibody against rabies virus targeting epitope I and/or epitope III of the rabies virus glycoprotein, developed in accordance with the WHO recommended “cocktail” therapeutic option targeting distinct antigenic sites. It demonstrates broad neutralization, low immunogenicity, and minimal interference with vaccine-induced active immunity Two products are both under NDA review in China. If approved, they will synergize with the Group’s existing products in expert networks and market resources   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, […]

China Medical System: Innovative Drug Oral JAK1 Inhibitor Povorcitinib Obtained IND Approval for the Indications of Vitiligo and Hidradenitis Suppurativa

  Povorcitinib is a selective oral small-molecule JAK1 Inhibitor, with the potential to provide a new treatment option for patients suffering from autoimmune and inflammatory dermatologic diseases On 28 August, Dermavon obtained IND approval for non-segmental vitiligo and moderate to severe hidradenitis suppurativa in China, and is actively preparing for initiating the relevant clinical trials Povorcitinib will synergize with Dermavon’s commercialized innovative drug ILUMETRI, exclusive drug Hirudoid and the innovative drug under development ruxolitinib phosphate cream, etc.   China Medical System Holdings Limited (“CMS”or the “Group” ) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details) together with its subsidiaries, received the drug clinical trial approval notice […]

Turnover and Profit Both Rise丨CMS (867.HK, 8A8.SG) 2025 Interim Performance Report in One Picture

ESG Honors | CMS Awarded “2025 ESG Exemplary Enterprise Award” at the International Green Zero-Carbon Festival

On July 18, 2025, at “The 4th International Green Zero-Carbon Festival & 2025 ESG Leadership Summit” held in Shanghai, China Medical System Holdings Limited (“CMS” or “the Group”) was honored with the “2025 ESG Exemplary Enterprise Award”. This award recognizes enterprises demonstrating systematic and pioneering practices across environmental, social, and governance dimensions. With its clear ESG strategy framework, quantifiable results, and continuous improvement mechanism, CMS has once again been highly recognized by authoritative institutions and the industry. Source: International Green Zero-Carbon Festival Official Website   With the theme of “Advancing Green Development, Toward Zero-Carbon Future”, the summit brought together over 200 enterprises and more than 100 industry leaders to discuss the industrial opportunities and transformation pathways under the dual carbon goal. This award is a full recognition of CMS’s long-term commitment to ESG values and innovation-driven sustainable development.   CMS has fully integrated the United Nations Sustainable Development Goals (SDGs) into the Group’s strategy, using top-level design to drive […]

China Medical System: NDA for the Improved New Drug ZUNVEYL for Alzheimer’s Disease Accepted in China

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.   About Product ZUNVEYL ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized […]